Similarly, the inhibition of CNOT7 and the enhancement of zeste homolog 2 (EZH2), miR-889, granulin-epithelin precursor (GEP), and MICA/B can successfully reverse NK cell resistance, suggesting that these molecules are promising targets for immunotherapy in HCC patients (105–109). The gene discussed is GRN; the disease is hepatocellular carcinoma.